Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
FENC
FENC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
FENC News
Fennec Pharmaceuticals Q4 2025 Earnings Report
6d ago
seekingalpha
FENNEC PHARMACEUTICALS INC Reports Q4 2025 Net Product Sales of $13.8 Million
6d ago
moomoo
Fennec Pharmaceuticals Announces Financial Results for Q4 and Full Year 2025 Along with Business Update
6d ago
moomoo
FENNEC PHARMACEUTICALS Reports FY Basic EPS of USD -0.35
6d ago
moomoo
FENNEC PHARMACEUTICALS REPORTS FY SALES OF $44.6 MILLION
6d ago
moomoo
Fennec Pharmaceuticals to Release Q4 Earnings on March 24
Mar 23 2026
Newsfilter
Solas Capital Management Acquires Stake in Euronet Worldwide
Mar 16 2026
Yahoo Finance
Solas Capital Initiates New Position in Kyndryl
Mar 06 2026
Fool
Fennec Pharmaceuticals Initiates PEDMARK® Clinical Study
Mar 04 2026
Newsfilter
PEDMARK® Shows Promise for Hearing Preservation in Head and Neck Cancer Patients
Feb 20 2026
Newsfilter
B. Riley Begins Coverage of Fennec Pharmaceuticals Inc. with a Buy Rating and $16 Price Target
Feb 12 2026
moomoo
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
Dec 26 2025
Globenewswire
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
Dec 26 2025
Newsfilter
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
Dec 26 2025
Yahoo Finance
Fennec Pharmaceuticals Initiates Study of PEDMARK® to Reduce Ototoxicity in Adult Testicular Cancer Patients
Dec 09 2025
Newsfilter
Pedmark Shows Promising Results in Japan Study — Reduced Hearing Loss with Equivalent Cancer-Fighting Efficacy
Dec 02 2025
Benzinga
Show More News
